Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051242 · ClinicalTrials.gov registry record · NA
Enhanced Bioscaffold for Volumetric Muscle Loss
A NA study, sponsored by J. Peter Rubin, MD.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT04051242 is a NA study that was terminated before completion, run by J. Peter Rubin, MD. The registered enrollment target is 10 participants.
The verdict
NCT04051242, a NA study, was terminated before completion, sponsored by J. Peter Rubin, MD.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after soft tissue trauma.
Interventions
- DEVICE XenMatrix™ AB Surgical Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2024-01-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04051242
The ClinicalTrials.gov registry entry for NCT04051242 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is J. Peter Rubin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XenMatrix™ AB Surgical Graft is the first listed.
NCT04051242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04051242 about?
NCT04051242 is a clinical study titled "Enhanced Bioscaffold for Volumetric Muscle Loss". This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after soft tissue trauma.
What is the current status of trial NCT04051242?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2020-02-10. Estimated completion is 2024-01-24.
What interventions are being tested in trial NCT04051242?
The interventions under investigation include: XenMatrix™ AB Surgical Graft (DEVICE).
Who is sponsoring clinical trial NCT04051242?
This trial is sponsored by J. Peter Rubin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.